Miramoon Pharma — Seed

BStartup10, Banco Sabadell's early-stage investment vehicle, led an undisclosed investment round in Miramoon Pharma alongside other private investors. The biotech will use the capital to advance regulatory preclinical studies of MP-004, a topical molecule targeting RyR2 calcium channels for retinitis pigmentosa, which holds orphan drug designation from both the FDA and the EMA; Columbus Venture Partners, Asabys and Alta Life Sciences were cited as specialist funds supporting the process rather than confirmed co-investors.